Biosurgery Market Size, Share, Growth, and Industry Analysis, Types (Hemostatic Agents, Surgical Sealants and Adhesives, Bone-Graft Substitutes, Soft-Tissue Attachments, Adhesion Barriers, Others), Applications (Neuro and spine surgery, Cardio and thoracic surgery, General surgery, Orthopaedic surgery, Others), and Regional Insights and Forecast to 2035
Buy Now - USD 3,580
Biosurgery Market Size
The Global Biosurgery Market size was USD 14.13 Billion in 2025 and is projected to touch USD 15.34 Billion in 2026, reach USD 16.66 Billion in 2027, and grow to USD 32.16 Billion by 2035, exhibiting a CAGR of 8.57% during the forecast period from 2026 to 2035. More than 58% of surgeons now use biosurgery products during complex procedures, while around 46% of hospitals are increasing adoption of advanced wound management and tissue repair technologies for improved patient recovery outcomes.
The US Biosurgery Market continues to expand because of increasing surgical procedure volumes, rising adoption of minimally invasive treatments, and strong healthcare technology investments. Nearly 51% of advanced healthcare centers in the country now use tissue sealants and hemostatic products during cardiovascular and orthopedic surgeries. Around 37% of hospitals are also investing in regenerative surgical materials and advanced wound healing technologies to improve patient safety and reduce recovery complications.
Key Findings
- Market Size: Valued at $14.13 Billion in 2025, projected to touch $15.34 Billion in 2026, reach $16.66 Billion in 2027, and grow to $32.16 Billion by 2035 at a CAGR of 8.57%.
- Growth Drivers: More than 58% advanced surgical adoption, 46% hospital biosurgery integration, 38% regenerative treatment demand, and 33% minimally invasive procedure growth observed.
- Trends: Around 44% hemostatic innovation, 35% tissue sealant development, 29% infection prevention focus, and 24% robotic-assisted surgery integration recorded.
- Key Players: Medtronic, Stryker, Baxter, Integra LifeSciences, Johnson & Johnson Information & Technology, Inc. & more.
- Regional Insights: North America held 37% share, Europe 28%, Asia-Pacific 26%, and Middle East & Africa 9% driven by healthcare modernization.
- Challenges: Nearly 38% regulatory delays, 31% high product cost pressure, 29% clinical testing complexity, and 27% healthcare budget limitations affect adoption.
- Industry Impact: Over 49% hospital modernization investment, 42% regenerative medicine focus, 38% minimally invasive surgery growth, and 33% healthcare technology expansion observed.
- Recent Developments: Around 24% bleeding control improvement, 22% supply efficiency increase, 21% tissue regeneration enhancement, and 19% leakage reduction achieved.
Biosurgery products are increasingly becoming important in modern healthcare because they improve surgical precision, support faster healing, and reduce post-operative complications. Nearly 32% of advanced hospitals now prefer bio-compatible surgical materials for complex procedures requiring tissue repair and bleeding control. Growing demand for minimally invasive surgeries and regenerative treatment technologies continues to support long-term market expansion worldwide.
Biosurgery Market Trends
The Biosurgery Market is growing steadily because hospitals and surgical centers are increasingly adopting advanced surgical care products that improve patient recovery and reduce operation-related complications. More than 58% of surgeons now prefer biosurgery products during complex surgical procedures to control bleeding and support faster healing. Around 46% of hospitals are using advanced hemostatic agents during cardiovascular and orthopedic surgeries to improve procedural efficiency. Surgical sealants and adhesives contribute nearly 24% of total biosurgery demand because of their growing use in minimally invasive surgeries and tissue closure applications. Nearly 39% of healthcare facilities are increasing the use of bone-graft substitutes to support orthopedic reconstruction and spinal procedures. Neuro and spine surgeries account for around 21% of biosurgery applications because of increasing neurological disorders and aging population trends. North America contributes nearly 37% of global demand due to advanced healthcare infrastructure and high surgical procedure volumes. Around 34% of medical institutions are also focusing on infection prevention technologies and bio-compatible surgical materials to improve patient safety and long-term treatment outcomes.
Biosurgery Market Dynamics
"Growth in minimally invasive surgical procedures"
The increasing adoption of minimally invasive surgeries is creating strong opportunities for the Biosurgery Market. Nearly 48% of hospitals now prefer advanced biosurgery products during laparoscopic and robotic-assisted procedures to improve healing and reduce blood loss. Around 33% of surgeons are increasing the use of surgical sealants and tissue adhesives for improved patient recovery and reduced surgical complications.
"Rising demand for advanced wound management solutions"
Healthcare providers are increasingly adopting biosurgery products to improve surgical efficiency and patient safety. More than 44% of surgical centers now use advanced hemostatic agents to reduce intraoperative bleeding. Around 36% of orthopedic and cardiovascular procedures involve biosurgery materials for tissue repair and post-surgical recovery support.
RESTRAINTS
"High product costs and limited accessibility"
The Biosurgery Market faces challenges because advanced surgical materials and bio-compatible products often involve high manufacturing and operational costs. Nearly 31% of smaller healthcare facilities report difficulty adopting premium biosurgery products because of budget limitations. Around 27% of hospitals in developing regions continue to depend on traditional surgical materials due to limited healthcare spending.
CHALLENGE
"Strict regulatory approval and product validation"
Regulatory compliance remains a major challenge for biosurgery manufacturers because surgical products require extensive testing and quality validation. More than 38% of product developers report delays linked to clinical evaluation and approval procedures. Around 29% of companies are increasing investment in safety testing and product documentation to meet healthcare regulatory requirements.
Segmentation Analysis
The Global Biosurgery Market size was USD 14.13 Billion in 2025 and is projected to touch USD 15.34 Billion in 2026, reach USD 16.66 Billion in 2027, and grow to USD 32.16 Billion by 2035, exhibiting a CAGR of 8.57% during the forecast period from 2026 to 2035. Market growth is supported by increasing surgical procedures, rising demand for minimally invasive treatments, and growing adoption of advanced wound management and tissue repair technologies across hospitals and specialty surgical centers worldwide.
By Type
Hemostatic Agents
Hemostatic agents remain the leading product category because they are widely used to control bleeding during surgical procedures and improve patient safety. Nearly 52% of major hospitals now use advanced hemostatic products in cardiovascular, neurological, and orthopedic surgeries to reduce blood loss and shorten operation time.
Hemostatic Agents Market Size reached USD 4.45 Billion in 2026, accounting for approximately 29% of the total market share. This segment is expected to grow at a CAGR of 8.9% from 2026 to 2035, supported by increasing surgical volumes and rising demand for efficient bleeding management solutions.
Surgical Sealants and Adhesives
Surgical sealants and adhesives are experiencing strong demand because they improve tissue closure and reduce surgical complications. Around 41% of minimally invasive procedures now involve advanced sealant technologies to improve recovery and reduce infection risks in complex surgeries and tissue repair procedures.
Surgical Sealants and Adhesives Market Size stood at USD 3.53 Billion in 2026 with nearly 23% market share. This segment is projected to grow at a CAGR of 8.8% during the forecast period because of rising adoption in minimally invasive and robotic-assisted surgeries.
Bone-Graft Substitutes
Bone-graft substitutes are increasingly used in orthopedic and spinal procedures because they support tissue regeneration and bone healing. Nearly 38% of orthopedic reconstruction procedures now use bio-compatible graft substitutes to improve structural stability and post-surgical recovery outcomes.
Bone-Graft Substitutes Market Size reached USD 2.91 Billion in 2026, representing approximately 19% market share. This segment is expected to grow at a CAGR of 8.5% from 2026 to 2035 due to increasing orthopedic surgeries and aging population trends.
Soft-Tissue Attachments
Soft-tissue attachment products continue to gain importance in sports medicine and orthopedic repair procedures. Around 29% of ligament and tendon repair surgeries now involve advanced soft-tissue fixation technologies for improved structural support and long-term recovery outcomes.
Soft-Tissue Attachments Market Size stood at USD 1.99 Billion in 2026 with around 13% market share. This segment is projected to expand at a CAGR of 8.2% during the forecast period because of increasing sports injuries and orthopedic treatment demand.
Adhesion Barriers
Adhesion barriers are increasingly adopted in abdominal and gynecological surgeries to reduce post-surgical complications and tissue adhesions. Nearly 24% of advanced surgical procedures now use adhesion prevention materials to improve recovery and reduce repeat surgical interventions.
Adhesion Barriers Market Size reached USD 1.53 Billion in 2026, accounting for approximately 10% market share. This segment is expected to grow at a CAGR of 8.1% from 2026 to 2035 because of increasing awareness regarding post-operative complication prevention.
Others
Other biosurgery products including regenerative biomaterials and specialty surgical solutions continue to support market expansion across healthcare sectors. Nearly 18% of specialized surgical centers are increasing the use of advanced biosurgery technologies for complex tissue repair and wound management applications.
Others Market Size stood at USD 0.93 Billion in 2026 with approximately 6% market share. This segment is projected to grow at a CAGR of 7.9% during the forecast period because of ongoing innovation in surgical biomaterials and regenerative healthcare products.
By Application
Neuro and spine surgery
Neuro and spine surgery applications are growing because of increasing neurological disorders and rising spinal treatment procedures. More than 34% of complex spinal surgeries now involve biosurgery products for bleeding control, tissue repair, and improved post-surgical recovery outcomes.
Neuro and spine surgery Market Size reached USD 3.53 Billion in 2026, accounting for approximately 23% market share. This segment is expected to grow at a CAGR of 8.7% from 2026 to 2035 because of rising spinal surgery demand and advanced neurosurgical procedures.
Cardio and thoracic surgery
Cardio and thoracic surgery remains a major application area because biosurgery products improve surgical precision and patient safety during critical cardiovascular procedures. Around 39% of cardiac surgeries now use advanced sealants and hemostatic agents for effective tissue management and reduced blood loss.
Cardio and thoracic surgery Market Size stood at USD 3.22 Billion in 2026 with nearly 21% market share. This segment is projected to grow at a CAGR of 8.9% during the forecast period because of increasing cardiovascular disease treatment procedures.
General surgery
General surgery applications continue to account for significant biosurgery demand because hospitals are increasing the use of advanced surgical care products in abdominal and minimally invasive procedures. Nearly 42% of general surgeries now involve tissue adhesives and bleeding management solutions for better patient outcomes.
General surgery Market Size reached USD 4.14 Billion in 2026, representing approximately 27% market share. This segment is expected to expand at a CAGR of 8.6% from 2026 to 2035 because of increasing surgical procedure volumes globally.
Orthopaedic surgery
Orthopaedic surgery is experiencing strong biosurgery adoption because of increasing sports injuries, bone reconstruction procedures, and aging-related joint disorders. Around 37% of orthopedic surgeries now use bone-graft substitutes and soft-tissue repair products for improved healing support.
Orthopaedic surgery Market Size stood at USD 3.07 Billion in 2026 with around 20% market share. This segment is projected to grow at a CAGR of 8.4% during the forecast period because of rising musculoskeletal treatment demand.
Others
Other surgical applications including gynecological and reconstructive procedures continue to support stable biosurgery demand. Nearly 21% of specialized surgical departments are increasing the use of bio-compatible surgical materials to improve recovery, minimize complications, and support long-term patient outcomes.
Others Market Size reached USD 1.38 Billion in 2026, accounting for approximately 9% market share. This segment is expected to grow at a CAGR of 7.8% from 2026 to 2035 due to increasing adoption of advanced surgical technologies.
Biosurgery Market Regional Outlook
The Global Biosurgery Market size was USD 14.13 Billion in 2025 and is projected to touch USD 15.34 Billion in 2026, reach USD 16.66 Billion in 2027, and grow to USD 32.16 Billion by 2035, exhibiting a CAGR of 8.57% during the forecast period from 2026 to 2035. Market growth is supported by rising surgical procedures, increasing use of minimally invasive treatments, and growing demand for advanced wound management and tissue repair products across healthcare systems worldwide.
North America
North America continues to dominate the Biosurgery Market because of advanced healthcare infrastructure and high surgical procedure volumes. Nearly 54% of major hospitals in the region now use advanced hemostatic agents and surgical sealants during cardiovascular and orthopedic surgeries. Rising adoption of minimally invasive procedures and robotic-assisted surgeries is also supporting market demand across healthcare facilities.
North America held around 37% share of the global Biosurgery Market in 2026, reaching approximately USD 5.68 Billion. The region continues to benefit from strong healthcare spending, increasing surgical innovation, and growing use of bio-compatible surgical materials in complex medical procedures.
Europe
Europe remains an important market because of increasing aging population, rising orthopedic procedures, and growing adoption of advanced surgical care products. Around 41% of hospitals in the region are increasing the use of tissue adhesives and wound management products to improve surgical efficiency and patient recovery outcomes.
Europe accounted for nearly 28% of the global market share in 2026, with a market value of approximately USD 4.30 Billion. Growing investments in healthcare modernization, rising cardiovascular treatment procedures, and increasing adoption of minimally invasive surgeries continue to support regional market growth.
Asia-Pacific
Asia-Pacific is experiencing strong growth in the Biosurgery Market because of expanding healthcare infrastructure and increasing surgical treatment demand. More than 47% of healthcare investments in the region are focused on improving surgical capabilities and advanced treatment technologies. Rising population levels and growing awareness regarding advanced surgical procedures are also contributing to market expansion.
Asia-Pacific held approximately 26% market share in 2026, reaching nearly USD 3.99 Billion. The market continues to expand because of increasing hospital development projects, growing healthcare accessibility, and rising adoption of advanced biosurgery products across emerging economies.
Middle East & Africa
The Middle East & Africa market is steadily growing because of increasing healthcare infrastructure investments and rising adoption of advanced surgical procedures. Nearly 24% of large healthcare facilities in the region are expanding surgical departments with advanced wound management and biosurgery technologies to improve patient treatment outcomes.
Middle East & Africa represented around 9% of the global Biosurgery Market in 2026, reaching approximately USD 1.38 Billion. Regional growth is supported by improving healthcare access, increasing medical tourism activities, and rising investments in modern hospital infrastructure.
List of Key Biosurgery Market Companies Profiled
- MAQUET Holding B.V. & Co. KG
- Medtronic
- Stryker
- Johnson & Johnson Information & Technology, Inc.
- Baxter
- BD
- Hemostasis, LLC
- B. Braun Melsungen AG
- Pfizer Inc
- Integra LifeSciences
- CSL Limited
- Sanofi
- CryoLife
- Samyang Biopharm
- Aroa Biosurgery Limited
- TELA Bio
- Tissue Regenix
- Osiris
Top Companies with Highest Market Share
- Johnson & Johnson Information & Technology, Inc.: Held nearly 18% market share supported by strong surgical product portfolio and global healthcare presence.
- Medtronic: Accounted for approximately 15% market share because of advanced biosurgery technologies and broad surgical treatment solutions.
Investment Analysis and Opportunities in Biosurgery Market
The Biosurgery Market is attracting strong investment because healthcare providers are increasingly adopting advanced surgical technologies and bio-compatible treatment materials. Nearly 49% of hospital modernization projects now include investments in advanced wound management and bleeding control solutions. Around 38% of healthcare institutions are increasing spending on minimally invasive surgical systems supported by tissue sealants and biosurgery products. Orthopedic and cardiovascular surgery centers are also increasing investments in bone-graft substitutes and regenerative surgical technologies to improve patient outcomes. Nearly 33% of medical device manufacturers are focusing on innovative biosurgery materials designed for faster healing and reduced post-surgical complications. North America receives approximately 41% of biosurgery-related healthcare investments because of high surgical procedure volumes and advanced healthcare infrastructure. In Asia-Pacific, around 36% of healthcare expansion projects now involve advanced surgical treatment technologies and modern hospital infrastructure. Opportunities are also increasing in robotic-assisted surgery, regenerative medicine, and bioengineered tissue repair solutions as healthcare providers continue focusing on patient recovery and procedural efficiency.
New Products Development
New product development in the Biosurgery Market is focused on improving surgical precision, reducing recovery time, and enhancing tissue regeneration capabilities. More than 44% of newly launched biosurgery products now include advanced hemostatic technologies for rapid bleeding control during complex surgeries. Around 35% of manufacturers are developing bio-compatible tissue sealants designed for minimally invasive and robotic-assisted procedures. Bone-graft substitute innovation is also increasing as healthcare providers demand stronger regenerative support for orthopedic reconstruction surgeries. Nearly 29% of new biosurgery solutions now focus on infection prevention and improved wound healing performance. Manufacturers are additionally introducing advanced adhesion barriers and soft-tissue repair products to reduce surgical complications and improve post-operative recovery. Demand for biologically derived surgical materials and regenerative healthcare products is also increasing because hospitals are focusing on faster healing, lower complication rates, and improved patient safety during surgical procedures.
Recent Developments
- Medtronic: Expanded its advanced hemostatic product portfolio in 2025, improving surgical bleeding control efficiency by nearly 24% during complex surgical procedures.
- Stryker: Introduced upgraded orthopedic biosurgery products in 2025 with approximately 21% improved tissue regeneration support for bone reconstruction surgeries.
- Baxter: Developed advanced tissue sealant technologies in 2025 capable of reducing post-surgical leakage risks by around 19% in minimally invasive procedures.
- Integra LifeSciences: Increased production of regenerative biosurgery materials in 2025, improving hospital supply efficiency by nearly 22% across surgical treatment centers.
- TELA Bio: Launched reinforced soft-tissue repair products in 2025 featuring approximately 18% improved structural durability for surgical reconstruction procedures.
Report Coverage
The Biosurgery Market report provides detailed analysis of surgical treatment trends, healthcare infrastructure development, product innovation, market segmentation, and regional demand patterns across the global biosurgery industry. The report studies major biosurgery product categories including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, soft-tissue attachments, adhesion barriers, and other advanced surgical materials used in modern healthcare systems.
The report also examines biosurgery applications across neuro and spine surgery, cardio and thoracic surgery, general surgery, orthopedic surgery, and specialized medical procedures. General surgery contributes approximately 27% of total market demand because hospitals increasingly use advanced biosurgery products during minimally invasive and abdominal surgeries. Cardio and thoracic surgery represents nearly 21% market share because advanced hemostatic agents and tissue sealants are becoming important during cardiovascular treatment procedures.
Regional analysis included in the report covers North America, Europe, Asia-Pacific, and Middle East & Africa. North America accounts for approximately 37% market share because of advanced healthcare infrastructure and high adoption of innovative surgical technologies. Europe contributes nearly 28% because of rising aging population and increasing orthopedic treatment demand. Asia-Pacific represents around 26% market share due to healthcare infrastructure expansion and growing surgical treatment accessibility, while Middle East & Africa holds approximately 9% because of improving hospital infrastructure and rising healthcare investments.
The report additionally studies competitive positioning of leading biosurgery companies operating in global healthcare markets. Nearly 42% of major manufacturers are investing in regenerative medicine technologies, advanced tissue repair products, and biologically derived surgical materials. Product development analysis highlights increasing demand for minimally invasive surgical technologies, infection prevention solutions, and bio-compatible healthcare materials. The report also covers healthcare spending trends, surgical procedure growth, hospital modernization activities, and emerging opportunities shaping long-term market expansion in the Biosurgery Market.
Biosurgery Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 14.13 Billion in 2026 |
|
|
Market Size Value By |
USD 32.16 Billion by 2035 |
|
|
Growth Rate |
CAGR of 8.57% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation 
Download FREE Sample
|
||
Frequently Asked Questions
-
What value is the Biosurgery Market expected to touch by 2035?
The global Biosurgery Market is expected to reach USD 32.16 Billion by 2035.
-
What CAGR is the Biosurgery Market expected to exhibit by 2035?
The Biosurgery Market is expected to exhibit a CAGR of 8.57% by 2035.
-
Who are the top players in the Biosurgery Market?
MAQUET Holding B.V. & Co. KG, Medtronic, Stryker, Johnson & Johnson Information & Technology, Inc., Baxter, BD, Hemostasis, LLC, B. Braun Melsungen AG, Pfizer Inc, Integra LifeSciences, CSL Limited, Sanofi, CryoLife, Samyang Biopharm, Aroa Biosurgery Limited, TELA Bio, Tissue Regenix, Osiris
-
What was the value of the Biosurgery Market in 2025?
In 2025, the Biosurgery Market value stood at USD 14.13 Billion.
Our Clients
Trusted & Certified
